A Study to Identify Biomarkers of Spinal Muscular Atrophy in Spinraza-Treated Patients

Overview

About this study

The purpose of this study is to identify biomarkers of spinal muscular atrophy in Spinraza-treated patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Inclusion criteria include SMA patients receiving Spinraza.
Males and females of all ages
Patients diagnosed with types 1-4.

Exclusion Criteria:

CSF drawn for an indication other than Spinraza injection would be excluded.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Linda Hasadsri, M.D., Ph.D.	Closed for enrollment	Contact information: Sara Cook M.D., Ph.D. (507)284-1196 Cook.Sara@mayo.edu
La Crosse, Wis. Mayo Clinic principal investigator Daniel Anderson, D.O.	Closed for enrollment	Contact information: Lisa Hines (507)293-1638 Hines.Lisa@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Linda Hasadsri, M.D., Ph.D.

Closed for enrollment

Contact information:

Sara Cook M.D., Ph.D.

(507)284-1196

Cook.Sara@mayo.edu

La Crosse, Wis.

Mayo Clinic principal investigator

Daniel Anderson, D.O.

Closed for enrollment

Contact information:

Lisa Hines

(507)293-1638

Hines.Lisa@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials